Hormone receptor positive breast cancer shows that ER or PgR receptor is over expressing in the cancer cell.
Recently, the treatment of breast cancer is thought to classify the breast cancer subclass based on the molecular marker before treatment.
These subtype is called luminal A/B and these patients is available of hormone therapy.
At the AACR, the biomarker to surrogate the good prognosis after treatment to these patients is reported.
This is related to PI3K/mTOR molecular pathway, and this pathway is famous for cellular growth regulation.
They said that the mutation of PI3K/mTOR could disturb the regulation of the correct cellular function.
ホルモン受容体陽性乳癌で予後不良と関連する可能性がある複数の蛋白質の変化が明らかとなった。PI3K/mTOR情報伝達系に制御されている、これらの蛋白質の変化が起こると、リンパ節陽性乳癌の悪性度が高くなるという。患者の検体を解析した結果、示されたもの。3月31日から4月4日にシカゴで開催されている米国癌研究会議（AACR）で、米University of Texas MD Anderson Cancer CenterのFunda Meric-bernstam氏によって発表された。追加試験によって、見いだされたマーカーの意義が確実となれば、従来のホルモン療法だけでは不十分な患者や分子標的薬による追加治療を受けた方が良い患者を同定できる可能性があるとしている。
ホルモン受容体陽性乳癌で予後不良と関連する可能性がある因子を同定【AACR2012】：日経メディカル
They found four aberrations that were predictors of overall survival. They remained significant even after multivariable analysis accounting for other factors such as age and node-positive status that also affect survival. They are:
- Increased phosphorylation of ribosomal protein S6 (pS6) and of translation initiation factor 4E-binding protein 1 (p4E-BP1).
- Increased expression of eukaryotic elongation factor 2 kinase (eEF2K).
- Decreased expression of programmed cell death protein 4 (pdcd4).
Their findings, if validated by additional studies, could lead to markers that help select patients who may have a high risk of relapse if treated with traditional endocrine therapy alone and identify those who might benefit from an additional targeted therapy, Meric-Bernstam noted.
PI3K/mTOR pathway proteins tied to poor prognosis in breast cancer | EurekAlert! Science News
Luminal A/B are majority of the breast cancer patients.
If this evidence would be confirmed in the future, many patients could take the appropriate therapy, such as high efficacy and low adverse effects.
